Navid Radfar: Moving Beyond CHA₂DS₂-VASc and De-Risking Atrial Fibrillation
Navid Radfar, Incoming Cardiology Fellow at Rutgers Health, shared on LinkedIn about a recent article he and his colleagues co-authored, published in American Journal of Cardiovascular Drugs, adding:
”Excited to share our new publication, ‘De-risking Atrial Fibrillation: Refining Anticoagulation Decision-Making,’ is now published in the American Journal of Cardiovascular Drugs.
Atrial fibrillation is the most common arrhythmia and a leading cause of stroke.
For years, we’ve decided who needs a blood thinner using one clinical checklist: the CHA₂DS₂-VASc score.
But does it really capture everything about a patient?
It’s practical, widely used, and has helped countless patients — yet it has a blind spot. It treats complex variables as simple yes/no boxes, and it can’t see the structure or function of the heart itself.
In this paper, my co-authors and I make the case for a more personalized approach we call ‘de-risking’ — using advanced imaging (left atrial strain, volume index, and appendage morphology), circulating biomarkers, and AI-enabled tools to refine who truly benefits from anticoagulation, and who may be exposed to bleeding risk without much to gain.
We also synthesize lessons from landmark trials (ARTESIA, NOAH-AFNET 6, and ALONE-AF) that collectively reinforce a key idea: anticoagulation decisions should follow individualized risk–benefit assessment, not arrhythmia detection alone.”
Title: De-risking Atrial Fibrillation: Refining Anticoagulation Decision-Making
Authors: Navid Radfar, Dhir Gala, Harsh Singh, Juan Bello, Joseph Allencherril
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 13, 2026, 18:39Lukas Röthlisberger: Real-World Evidence on Effectiveness and Safety of Rivaroxaban in Children
-
Aug 13, 2026, 18:36Soner Yilmaz: Blood Safety in Türkiye Through More Than 22.5 Million Blood Donations
-
Aug 13, 2026, 18:31Muthukumarasamy Raja: FDA Approval of EZPLAZ Marks a Breakthrough in Emergency Plasma Care
-
Aug 13, 2026, 18:29Peter Zdziarski: Protecting Our Community While Creating a Future Where We Are No Longer Needed
-
Aug 13, 2026, 18:29Morgan E Amos: Thrilled to Receive the Student Research Award From HTRS
-
Aug 13, 2026, 16:38Sheharyar Raza: Plasma Exchange in Multiple Sclerosis
-
Aug 13, 2026, 16:31Juan Manuel Cisneros Carrasco: The True Cost of Blood Donation
-
Aug 13, 2026, 16:25Connie Montgomery: Bridging the Gap Between Patients, Culture and Clinical Trials
-
Aug 13, 2026, 16:16Isabella Presch: A New AI Approach to Protein Engineering